Loading…
Loading…
Innate Pharma NASDAQ: IPHA said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs and its preclinical antibody-drug conjugate, or ADC, portfolio.
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.
Swedish Orphan Biovitrum AB (Sobi) and Innate Pharma SA (NASDAQ:IPHA) on Monday forged a strategic alliance to launch a critical Phase 3 clinical trial targeting a rare form of skin cancer.
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in Sézary syndrome.
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026, succeeding So.
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T-cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLO.
Innate Pharma has an interesting lineup of catalysts with the upcoming IPH4502 data, PACIFIC-9 results, and a potential financing solution for TELLOMAK-3. IPH4502's early responses across several solid tumors also give it some diversification beyond Monalizumab. PACIFIC-9 is IPHA's largest near-term catalyst, but AstraZeneca controls it, and IPHA is only eligible for milestone payments and royalties if it succeeds.